Accuray Incorporated (ARAY)

Market Cap	184.03M
Revenue (ttm)	444.20M
Net Income (ttm)	-16.53M
Shares Out	100.57M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	583,692
Open	1.840
Previous Close	1.840
Day's Range	1.765 - 1.870
52-Week Range	1.400 - 3.050
Beta	1.40
Analysts	Strong Buy
Price Target	9.00 (+391.8%)
Earnings Date	Nov 6, 2024

About ARAY

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 8, 2007
• Employees: 987
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAY
• Website: https://www.accuray.com

Financial Performance

In 2024, Accuray's revenue was $446.55 million, a decrease of -0.24% compared to the previous year's $447.61 million. Losses were -$15.55 million, 67.5% more than in 2023.

Analyst Forecast

According to one analyst, the rating for ARAY stock is "Strong Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(391.80% upside)

Analyst Consensus: Strong Buy